The University of Chicago Header Logo

Connection

Richard Schilsky to Clinical Trials as Topic

Back to Details
This is a "connection" page, showing publications Richard Schilsky has written about Clinical Trials as Topic.
Richard Schilsky
Connection Strength
7.230
Clinical Trials as Topic
  1. Continuing to Broaden Eligibility Criteria to Make Clinical Trials More Representative and Inclusive: ASCO-Friends of Cancer Research Joint Research Statement. Clin Cancer Res. 2021 05 01; 27(9):2394-2399.
    View in: PubMed
    Score: 0.464
  2. Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement. J Clin Oncol. 2017 Nov 20; 35(33):3737-3744.
    View in: PubMed
    Score: 0.368
  3. Modernizing Eligibility Criteria for Molecularly Driven Trials. J Clin Oncol. 2015 Sep 01; 33(25):2815-20.
    View in: PubMed
    Score: 0.316
  4. Integrating biomarkers in colorectal cancer trials in the West and China. Nat Rev Clin Oncol. 2015 Sep; 12(9):553-60.
    View in: PubMed
    Score: 0.312
  5. Innovative clinical trials for development of personalized cancer medicine. Mol Oncol. 2015 May; 9(5):933-4.
    View in: PubMed
    Score: 0.308
  6. Wither the cooperative groups? J Clin Oncol. 2014 Jan 20; 32(3):251-4.
    View in: PubMed
    Score: 0.278
  7. Publicly funded clinical trials and the future of cancer care. Oncologist. 2013; 18(2):232-8.
    View in: PubMed
    Score: 0.266
  8. Development and use of integral assays in clinical trials. Clin Cancer Res. 2012 Mar 15; 18(6):1540-6.
    View in: PubMed
    Score: 0.250
  9. Using patient-initiated study participation in the development of evidence for personalized cancer therapy. Clin Cancer Res. 2011 Nov 01; 17(21):6651-7.
    View in: PubMed
    Score: 0.244
  10. Clinical trials in the era of personalized oncology. CA Cancer J Clin. 2011 Nov-Dec; 61(6):365-81.
    View in: PubMed
    Score: 0.244
  11. Accrual to cancer clinical trials in the era of molecular medicine. Sci Transl Med. 2011 Mar 23; 3(75):75cm9.
    View in: PubMed
    Score: 0.234
  12. Optimizing collection of adverse event data in cancer clinical trials supporting supplemental indications. J Clin Oncol. 2010 Dec 01; 28(34):5046-53.
    View in: PubMed
    Score: 0.226
  13. Data submission standards and evidence requirements. Oncologist. 2010; 15(5):488-91.
    View in: PubMed
    Score: 0.215
  14. Personalizing cancer care: American Society of Clinical Oncology presidential address 2009. J Clin Oncol. 2009 Aug 10; 27(23):3725-30.
    View in: PubMed
    Score: 0.208
  15. Introduction: contributions of the cooperative groups. Semin Oncol. 2008 Oct; 35(5):459.
    View in: PubMed
    Score: 0.197
  16. American Society of Clinical Oncology Statement on minimum standards and exemplary attributes of clinical trial sites. J Clin Oncol. 2008 May 20; 26(15):2562-7.
    View in: PubMed
    Score: 0.191
  17. Ethical, scientific, and regulatory perspectives regarding the use of placebos in cancer clinical trials. J Clin Oncol. 2008 Mar 10; 26(8):1371-8.
    View in: PubMed
    Score: 0.188
  18. The role of cooperative groups in cancer clinical trials. Cancer Treat Res. 2007; 132:111-29.
    View in: PubMed
    Score: 0.175
  19. Defining the role of pragmatic clinical trials in cancer clinical research: outcomes of a collaborative workshop hosted by the European Organisation for Research and Treatment of Cancer. Lancet Oncol. 2025 May; 26(5):e253-e263.
    View in: PubMed
    Score: 0.155
  20. End points in cancer clinical trials and the drug approval process. Clin Cancer Res. 2002 Apr; 8(4):935-8.
    View in: PubMed
    Score: 0.126
  21. Impact of Broadening Trial Eligibility Criteria for Patients with Advanced Non-Small Cell Lung Cancer: Real-World Analysis of Select ASCO-Friends Recommendations. Clin Cancer Res. 2021 05 01; 27(9):2430-2434.
    View in: PubMed
    Score: 0.116
  22. Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Prior Therapies Work Group. Clin Cancer Res. 2021 05 01; 27(9):2408-2415.
    View in: PubMed
    Score: 0.116
  23. Early Impact of COVID-19 on the Conduct of Oncology Clinical Trials and Long-Term Opportunities for Transformation: Findings From an American Society of Clinical Oncology Survey. JCO Oncol Pract. 2020 Jul; 16(7):417-421.
    View in: PubMed
    Score: 0.110
  24. Challenges and approaches to implementing master/basket trials in oncology. Blood Adv. 2019 07 23; 3(14):2237-2243.
    View in: PubMed
    Score: 0.104
  25. Accelerating anticancer drug development - opportunities and trade-offs. Nat Rev Clin Oncol. 2018 12; 15(12):777-786.
    View in: PubMed
    Score: 0.100
  26. Trial Reporting in Immuno-Oncology (TRIO): An American Society of Clinical Oncology-Society for Immunotherapy of Cancer Statement. J Clin Oncol. 2019 01 01; 37(1):72-80.
    View in: PubMed
    Score: 0.099
  27. Trial Reporting in Immuno-Oncology (TRIO): an American society of clinical oncology-society for immunotherapy of cancer statement. J Immunother Cancer. 2018 10 19; 6(1):108.
    View in: PubMed
    Score: 0.099
  28. Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012. J Clin Oncol. 2016 11 20; 34(33):3992-3999.
    View in: PubMed
    Score: 0.086
  29. Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015. J Clin Oncol. 2016 Jan 10; 34(2):179-85.
    View in: PubMed
    Score: 0.080
  30. Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial. Ann Oncol. 2015 Aug; 26(8):1791-8.
    View in: PubMed
    Score: 0.078
  31. Generalizability of trial results to elderly Medicare patients with advanced solid tumors (Alliance 70802). J Natl Cancer Inst. 2015 Jan; 107(1):336.
    View in: PubMed
    Score: 0.075
  32. Designing therapeutic clinical trials for older and frail adults with cancer: U13 conference recommendations. J Clin Oncol. 2014 Aug 20; 32(24):2587-94.
    View in: PubMed
    Score: 0.074
  33. American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol. 2014 Apr 20; 32(12):1277-80.
    View in: PubMed
    Score: 0.072
  34. Biological, clinical, and psychosocial correlates at the interface of cancer and aging research. J Natl Cancer Inst. 2012 Apr 18; 104(8):581-9.
    View in: PubMed
    Score: 0.063
  35. Patient advocates' role in clinical trials: perspectives from Cancer and Leukemia Group B investigators and advocates. Cancer. 2012 Oct 01; 118(19):4801-5.
    View in: PubMed
    Score: 0.062
  36. WIN Consortium--challenges and advances. Nat Rev Clin Oncol. 2011 Mar; 8(3):133-4.
    View in: PubMed
    Score: 0.058
  37. The next phase of chemoprevention research. Cancer Prev Res (Phila). 2011 Mar; 4(3):293-5.
    View in: PubMed
    Score: 0.058
  38. Ethics of mandatory research biopsy for correlative end points within clinical trials in oncology. J Clin Oncol. 2010 May 20; 28(15):2635-40.
    View in: PubMed
    Score: 0.055
  39. Toward efficient trials in colorectal cancer: the ARCAD Clinical Trials Program. J Clin Oncol. 2010 Feb 01; 28(4):527-30.
    View in: PubMed
    Score: 0.053
  40. Translating the cancer genome into clinically useful tools and strategies. Dis Model Mech. 2009 Sep-Oct; 2(9-10):426-9.
    View in: PubMed
    Score: 0.053
  41. A concise history of the cancer and leukemia group B. Clin Cancer Res. 2006 Jun 01; 12(11 Pt 2):3553s-5s.
    View in: PubMed
    Score: 0.042
  42. The cancer and leukemia group B pharmacology and experimental therapeutics committee: a historical perspective. Clin Cancer Res. 2006 Jun 01; 12(11 Pt 2):3612s-6s.
    View in: PubMed
    Score: 0.042
  43. First-line treatment options for patients with metastatic colorectal cancer. Nat Clin Pract Oncol. 2004 Dec; 1(2):70-1.
    View in: PubMed
    Score: 0.038
  44. Cetuximab in the treatment of colorectal cancer. Clin Adv Hematol Oncol. 2004 Nov; 2(11):1-10; quiz 11-12.
    View in: PubMed
    Score: 0.038
  45. Molecular profiling of 888 pediatric tumors informs future precision trials and data-sharing initiatives in pediatric cancer. Nat Commun. 2024 Jul 11; 15(1):5837.
    View in: PubMed
    Score: 0.037
  46. 3rd EORTC-NCI International Meeting on Cancer Molecular Markers: From Discovery to Clinical Practice. Expert Rev Mol Diagn. 2004 Jul; 4(4):431-3.
    View in: PubMed
    Score: 0.037
  47. Oncology physician and nurse practices and attitudes regarding offering clinical trial results to study participants. J Natl Cancer Inst. 2004 Apr 21; 96(8):629-32.
    View in: PubMed
    Score: 0.036
  48. Are targeted therapies really targeted? Clin Adv Hematol Oncol. 2003 Dec; 1(12):722-3.
    View in: PubMed
    Score: 0.035
  49. Oral fluoropyrimidine treatment of colorectal cancer. Clin Colorectal Cancer. 2001 Aug; 1(2):95-103.
    View in: PubMed
    Score: 0.030
  50. Recommendations to Streamline and Standardize Clinical Trial Site Feasibility Assessments: An ASCO Research Statement. JCO Oncol Pract. 2021 01; 17(1):41-51.
    View in: PubMed
    Score: 0.029
  51. American Society of Clinical Oncology Road to Recovery Report: Learning From the COVID-19 Experience to Improve Clinical Research and Cancer Care. J Clin Oncol. 2021 01 10; 39(2):155-169.
    View in: PubMed
    Score: 0.029
  52. Pharmacology and clinical status of capecitabine. Oncology (Williston Park). 2000 Sep; 14(9):1297-306; discussion 1309-11.
    View in: PubMed
    Score: 0.028
  53. Eniluracil: an irreversible inhibitor of dihydropyrimidine dehydrogenase. Expert Opin Investig Drugs. 2000 Jul; 9(7):1635-49.
    View in: PubMed
    Score: 0.028
  54. The promise of Immuno-oncology: implications for defining the value of cancer treatment. J Immunother Cancer. 2019 05 17; 7(1):129.
    View in: PubMed
    Score: 0.026
  55. Streamlining Adverse Events Reporting in Oncology: An American Society of Clinical Oncology Research Statement. J Clin Oncol. 2018 02 20; 36(6):617-623.
    View in: PubMed
    Score: 0.023
  56. Adjuvant therapy of colon cancer. Semin Oncol. 1995 Dec; 22(6):600-10.
    View in: PubMed
    Score: 0.020
  57. Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval. J Natl Cancer Inst. 2015 Nov; 107(11).
    View in: PubMed
    Score: 0.020
  58. Antifolates: the next generation. Semin Oncol. 1992 Dec; 19(6):707-19.
    View in: PubMed
    Score: 0.016
  59. Cancer and Leukemia Group B Pathology Committee guidelines for tissue microarray construction representing multicenter prospective clinical trial tissues. J Clin Oncol. 2011 Jun 01; 29(16):2282-90.
    View in: PubMed
    Score: 0.015
  60. An accelerated pathway for targeted cancer therapies. Nat Rev Drug Discov. 2011 02; 10(2):79-80.
    View in: PubMed
    Score: 0.014
  61. Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation. J Natl Cancer Inst. 2010 Nov 17; 102(22):1698-705.
    View in: PubMed
    Score: 0.014
  62. Refocusing the war on cancer: the critical role of personalized treatment. Sci Transl Med. 2010 Apr 21; 2(28):28cm13.
    View in: PubMed
    Score: 0.014
  63. Tomorrow's cancer treatments today: the first 50 years of the Cancer and Leukemia Group B. Semin Oncol. 2008 Oct; 35(5):470-83.
    View in: PubMed
    Score: 0.012
  64. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol. 2006 Feb; 33(1):15-49.
    View in: PubMed
    Score: 0.010
  65. Colorectal adenomas: a prototype for the use of surrogate end points in the development of cancer prevention drugs. Clin Cancer Res. 2004 Jun 01; 10(11):3908-18.
    View in: PubMed
    Score: 0.009
  66. Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin. Ann Intern Med. 1979 Jun; 90(6):929-31.
    View in: PubMed
    Score: 0.006
  67. Adjuvant therapy for colorectal cancer. Curr Probl Surg. 1997 Aug; 34(8):601-76.
    View in: PubMed
    Score: 0.006
  68. Chemotherapy for testicular cancer: current status of the National Cancer Institute Combined Modality Trial. Cancer Treat Rep. 1979 Sep-Oct; 63(9-10):1687-92.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.